Get started
Author

Marco Reyes-Martinez

Observed name: Marco A. Reyes-Martinez
OpenAlex ID: A5018350039
Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application
2020 · Jiyoon Bu, Ashita Nair, et al. · Biosensors and Bioelectronics · 43
PDF
Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).
2020 · Anika Agarwal, Jennifer Modliszewski, et al. · Journal of Clinical Oncology · 9
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
2024 · Daniel J. George, Susan Halabi, et al. · Journal of Clinical Oncology · 4
PDF
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
2023 · Daniel J. George, Susan Halabi, et al. · Journal of Clinical Oncology · 4
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
2023 · Tian Zhang, Lauren Howard, et al. · Journal of Clinical Oncology · 1
Abstract 6439: CapioCyte™ technology for efficient capture and downstream analysis of circulating tumor cells from renal cell carcinoma
2020 · Jiyoon Bu, Michael J. Poellmann, et al. · Cancer Research · 1
Abstract 5702: Characterization of circulating tumor cells during immune checkpoint inhibition in metastatic renal cell carcinoma and malignant melanoma
2018 · Tian Zhang, SinJung Park, et al. · Cancer Research · 1
Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
2026 · Robert Bruce Montgomery, Lauren Howard, et al. · Journal of Clinical Oncology
PDF
Abstract C117: Serum dehydroepiandrosterone sulfate (DHEAS) and race associated with longer survival in patients (pts) treated with apalutamide (Apa) and abiraterone acetate (AA) plus prednisone (P) in the PANTHER study
2025 · Daniel J. George, Lauren E. Howard, et al. · Cancer Epidemiology Biomarkers & Prevention
Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).
2025 · Patrick O'Shea, Matthew Labriola, et al. · Journal of Clinical Oncology
PDF
Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
2025 · Daniel J. George, Lauren Howard, et al. · Journal of Clinical Oncology
Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.
2025 · Jennifer A. Freedman, Sean Piwarski, et al. · Journal of Clinical Oncology
PDF
Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.
2025 · Elahe A. Mostaghel, Jennifer A. Freedman, et al. · Journal of Clinical Oncology
PDF
Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).
2020 · Tian Zhang, Yuan Wu, et al. · Journal of Clinical Oncology
Works count: 14
Citation count: 63
H-index: 4
I10-index: 1
Year
Topic
Type